- Home
- VSTM vs PSNL Comparison
VSTM vs PSNL Comparison
Compare VSTM & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- PSNL
- Stock Information
- Founded
- VSTM 2010
- PSNL 2011
- Country
- VSTM United States
- PSNL United States
- Employees
- VSTM N/A
- PSNL N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- VSTM Health Care
- PSNL Health Care
- Exchange
- VSTM Nasdaq
- PSNL Nasdaq
- Market Cap
- VSTM 239.9M
- PSNL 245.1M
- IPO Year
- VSTM 2012
- PSNL 2019
- Fundamental
- Price
- VSTM $4.22
- PSNL $6.12
- Analyst Decision
- VSTM Strong Buy
- PSNL Strong Buy
- Analyst Count
- VSTM 8
- PSNL 4
- Target Price
- VSTM $12.00
- PSNL $7.31
- AVG Volume (30 Days)
- VSTM 1.1M
- PSNL 1.2M
- Earning Date
- VSTM 11-06-2024
- PSNL 11-06-2024
- Dividend Yield
- VSTM N/A
- PSNL N/A
- EPS Growth
- VSTM N/A
- PSNL N/A
- EPS
- VSTM N/A
- PSNL N/A
- Revenue
- VSTM $10,000,000.00
- PSNL $87,489,000.00
- Revenue This Year
- VSTM N/A
- PSNL $15.76
- Revenue Next Year
- VSTM $53.90
- PSNL $4.02
- P/E Ratio
- VSTM N/A
- PSNL N/A
- Revenue Growth
- VSTM N/A
- PSNL 24.05
- 52 Week Low
- VSTM $2.10
- PSNL $1.12
- 52 Week High
- VSTM $14.22
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- VSTM 47.50
- PSNL 73.18
- Support Level
- VSTM $4.18
- PSNL $3.37
- Resistance Level
- VSTM $4.85
- PSNL $4.14
- Average True Range (ATR)
- VSTM 0.42
- PSNL 0.45
- MACD
- VSTM -0.14
- PSNL 0.25
- Stochastic Oscillator
- VSTM 10.70
- PSNL 95.07
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.